Single-Use Bioprocessing Systems Market Size and Forecast 2032

Market Overview

The Single-Use Bioprocessing Systems Market is projected to grow from USD 24,917.63 million in 2023 to an estimated USD 85,285.12 million by 2032, with a compound annual growth rate (CAGR) of 14.65% from 2024 to 2032. This rapid growth can be attributed to increasing demand for biopharmaceutical products and the widespread adoption of single-use technologies due to their flexibility, cost-effectiveness, and reduced risk of contamination.

Market drivers include the rising demand for biologics, increasing production of vaccines, and advancements in bioprocessing technologies. The shift from traditional stainless-steel systems to single-use systems has been driven by their ability to offer cost reduction, scalability, and faster turnaround times. Additionally, growing investments in biopharmaceutical R&D and the increasing trend towards personalized medicine are fueling the adoption of single-use technologies. The trend towards sustainability, with a reduced environmental footprint, further propels market growth.

Geographically, North America dominates the Single-Use Bioprocessing Systems market due to the region's well-established biopharmaceutical industry and significant investments in research and development. Europe and Asia-Pacific are also witnessing significant growth, driven by increasing manufacturing capabilities and demand for biopharmaceutical products. Key players in the market include Thermo Fisher Scientific, Sartorius AG, Merck KGaA, GE Healthcare, and Pall Corporation, among others, who are focusing on product innovation and strategic partnerships to strengthen their market position.

Market Insights

• The Single-Use Bioprocessing Systems market is projected to grow from USD 24,917.63 million in 2023 to USD 85,285.12 million by 2032, with a CAGR of 14.65% from 2024 to 2032.
• Key drivers include the increasing demand for biologics, advancements in bioprocessing technologies, and the shift towards cost-effective, flexible single-use systems in biopharmaceutical production.
• The ability of single-use systems to reduce operational costs, eliminate cleaning requirements, and scale production efficiently drives their widespread adoption.
• Limited reusability of single-use components and environmental concerns around plastic waste remain challenges in the market.
• Ongoing innovations, such as automation and AI integration, are enhancing the efficiency and precision of single-use bioprocessing systems.
• North America holds the largest market share, driven by a strong biopharmaceutical sector and high investments in R&D and innovation.
• Asia-Pacific is a fast-growing region, driven by increasing biomanufacturing capabilities, lower operational costs, and growing demand for biologics.

Market Drivers

Increasing Demand for Biopharmaceuticals and Biologics

One of the key drivers of the single-use bioprocessing systems market is the growing demand for biopharmaceuticals and biologics. Biologics, which include therapeutic proteins, monoclonal antibodies, and vaccines, have revolutionized the healthcare industry in recent years. For instance, the biologics market is projected to reach 4,400 kiloliters by 2027, a significant increase from 2,500 kiloliters in 2022, indicating a robust growth trajectory driven by the rising need for therapeutic proteins and vaccines. With the aging global population and increasing prevalence of chronic diseases, the demand for these biologics has surged. The approval of numerous novel biologic treatments, including gene therapies and monoclonal antibodies, has also increased, with 2020 witnessing more approvals than any other year in the last decade. This trend underscores the critical role of biologics in addressing chronic diseases and enhancing patient outcomes.Single-use bioprocessing systems offer an efficient and scalable solution to meet this growing demand by reducing production costs and improving flexibility. Traditional bioreactor systems, typically stainless-steel-based, require complex cleaning and sterilization processes between batches, which can slow down production and increase costs. Single-use systems, in contrast, are designed for one-time use, eliminating the need for such procedures. This not only shortens production timelines but also lowers operational costs, making single-use systems an attractive option for biopharmaceutical manufacturers. The shift towards biologics for personalized and targeted therapies further accelerates the demand for these advanced bioprocessing technologies, positioning single-use systems as a crucial enabler for meeting the industry’s evolving needs.

Cost-Effectiveness and Operational Efficiency

The increasing pressure on biopharmaceutical manufacturers to reduce production costs while maintaining high product quality has significantly contributed to the growth of the single-use bioprocessing systems market. Single-use technologies provide a cost-effective solution by eliminating the need for extensive capital investments in stainless-steel infrastructure, such as large-scale reactors, piping, and tanks. The reduced requirement for cleaning, validation, and maintenance further cuts down operating costs. Single-use systems also offer greater flexibility in scaling up or down based on production needs, which is essential for manufacturers working with varying batch sizes. The elimination of the need for dedicated cleaning equipment, along with reduced energy and water consumption, translates to further operational efficiencies. This makes single-use bioprocessing systems an ideal choice for both large-scale production facilities and smaller, more agile biotech companies. The cost-effectiveness of these systems is especially evident in the production of clinical trial materials or small batch runs, where traditional bioreactors may not be as economically viable.As the focus on cost reduction continues to grow, the adoption of single-use bioprocessing systems will likely increase, making them a central component of the modern biopharmaceutical production process.

Technological Advancements and Innovations in Single-Use Systems

Technological advancements in single-use bioprocessing systems are a key driver for the market’s growth. As the biopharmaceutical industry continues to evolve, there is an increasing demand for systems that offer higher performance, better reliability, and increased automation. Innovations in single-use technologies, such as advanced sensors, controls, and data analytics, have enabled manufacturers to achieve higher process precision and real-time monitoring, leading to enhanced process optimization.Furthermore, the integration of digital technologies such as artificial intelligence (AI) and machine learning into these systems is improving predictive maintenance, reducing downtime, and enhancing overall efficiency in the production process. Another important innovation is the development of new materials for single-use components that enhance product safety and performance. For example, using more robust and chemically resistant materials helps reduce the risk of product contamination and ensures greater stability in producing sensitive biologic drugs.The continuous improvements in system designs and materials combined with an increasing number of suppliers entering the market will continue to drive the adoption of single-use systems. This enables biomanufacturers to optimize their operations and produce high-quality biologic products more efficiently.

 Regulatory Support and Favorable Market Conditions

The regulatory landscape has increasingly become supportive of single-use bioprocessing systems, contributing to their widespread adoption. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have recognized the benefits of single-use systems in improving production flexibility and reducing risks associated with cross-contamination.For instance, these organizations have provided guidance on using disposable components in biomanufacturing, further validating their use in commercial production settings. The ease of validation and faster approval timelines for single-use systems also make them an attractive choice for manufacturers looking to expedite their product development cycles.The ability to quickly switch between different production runs while avoiding lengthy cleaning and sterilization procedures means that manufacturers can more efficiently meet regulatory requirements for clinical trials and commercial production. As governments and regulatory agencies continue to support using single-use technologies, the market for single-use bioprocessing systems is expected to grow.Additionally, the increasing trend of outsourcing drug manufacturing to Contract Development and Manufacturing Organizations (CDMOs) is accelerating demand for single-use systems as these organizations require flexible, scalable, and cost-effective solutions to meet their clients' diverse needs.

Market Trends

Increased Adoption of Hybrid Bioprocessing Systems

A growing trend in the Single-Use Bioprocessing Systems market is the adoption of hybrid systems, combining single-use technologies with traditional stainless-steel equipment. These hybrid systems allow manufacturers to take advantage of the benefits of both technologies, enabling them to scale up production while maintaining cost-effectiveness and flexibility. Hybrid systems are particularly advantageous for biopharmaceutical companies that require a combination of batch processing and continuous manufacturing. For instance, the combination of single-use bags for upstream processes, such as cell culture, alongside stainless-steel chromatography columns for downstream purification, allows companies to optimize their workflows. This hybrid approach not only facilitates rapid process development but also significantly reduces capital expenditure and operational costs associated with extensive cleaning and sterilization processes typical of traditional systems. Furthermore, the flexibility of hybrid systems is crucial for addressing the diverse needs of biopharmaceutical products. For example, a facility might utilize a single-use seed reactor to initiate cell growth and then transition to a larger, durable production reactor, effectively balancing the benefits of both technologies. This adaptability is particularly beneficial in scenarios where manufacturers must respond quickly to changes in product demand or regulatory requirements.Additionally, this hybrid approach addresses the unique demands of different product types, such as vaccines or cell therapies, which may require different production processes. The flexibility offered by hybrid bioprocessing systems allows manufacturers to adapt quickly to market fluctuations or changes in production volumes, ensuring they remain competitive and cost-efficient in the rapidly evolving biopharmaceutical industry. This trend reflects a shift toward greater versatility in manufacturing processes, accommodating a wider range of biopharmaceutical products while maximizing resource efficiency.

Focus on Sustainability and Environmental Impact

Sustainability has become a key focus in the Single-Use Bioprocessing Systems market, driven by increasing awareness of the environmental impact of biomanufacturing processes. Traditional biomanufacturing methods, particularly those relying on stainless-steel systems, generate significant waste due to the frequent need for cleaning, sterilization, and the disposal of contaminated components. Single-use systems, by their nature, eliminate the need for such processes, resulting in less water and energy consumption. However, there is still a growing focus on further enhancing the environmental sustainability of single-use systems. Manufacturers are now exploring more environmentally friendly materials for disposable components, such as bioplastics, and improving the recyclability of single-use parts. This trend is driven by both regulatory pressures and consumer demand for greener, more sustainable manufacturing practices.Additionally, several biopharmaceutical companies are adopting "closed-loop" systems, which minimize waste and streamline the entire production process, further enhancing sustainability. The increased attention to sustainability within the biopharmaceutical industry is also reflected in the growing market for “green” bioprocessing technologies, which aim to reduce the environmental footprint of drug manufacturing while maintaining efficiency and product quality. This shift towards more sustainable bioprocessing systems is likely to become a major long-term driver of market growth as both regulatory and consumer expectations evolve.

Integration of Advanced Automation and Digitalization

Another significant trend in the Single-Use Bioprocessing Systems market is the integration of advanced automation and digitalization. Biopharmaceutical companies are increasingly relying on automation to improve the efficiency, consistency, and scalability of their operations. Automation systems integrated into single-use bioprocessing setups provide greater control over the manufacturing process, reducing human error and ensuring that processes are carried out with precision and repeatability. Real-time monitoring of parameters such as temperature, pressure, and pH, combined with automated control systems, allows manufacturers to optimize production yields and maintain consistent product quality across batches.In addition, digitalization and the use of data analytics play a key role in process optimization. By collecting and analyzing data throughout the production process, manufacturers can identify inefficiencies, predict maintenance needs, and improve overall yield. Moreover, the application of artificial intelligence (AI) and machine learning (ML) is helping manufacturers optimize bioprocesses further, predict potential failures, and automate decision-making. This integration of automation and digital tools also supports the Industry 4.0 movement within biomanufacturing, which aims to create more flexible, intelligent, and efficient manufacturing environments. The trend towards automation and digitalization is transforming the way biopharmaceutical products are developed, produced, and delivered, offering enhanced control, reduced costs, and faster time-to-market for new therapies.

Expansion of Cell and Gene Therapies

The rapid growth of cell and gene therapies is another major trend driving the demand for single-use bioprocessing systems. These advanced therapies involve modifying a patient's cells or genes to treat or cure diseases and require highly specialized manufacturing processes. Single-use systems are ideal for this purpose because they offer the flexibility and scalability necessary to produce small specialized batches for clinical trials or commercial production. Additionally, using single-use bioreactors and other disposable components helps minimize contamination risk when working with live cells or genetic material.The expansion of cell and gene therapies is being fueled by significant investments in research and development as well as increasing regulatory support for advanced therapies. As these therapies are often highly individualized, quickly adapting production lines to different cell types or therapeutic modalities is essential. Single-use bioprocessing systems-with their modular design and low capital investment requirements-are particularly suited to meet these needs. The growth of cell and gene therapy markets is expected to continue driving adoption of single-use technologies that can accommodate these innovative treatments' unique demands. This trend reflects a broader shift towards personalized medicine where therapies are tailored to individual patients' genetic profiles and underscores flexible manufacturing technologies' pivotal role in advancing these next-generation treatments.

Market Challenges

Limited Material Reusability and Environmental Concerns

One of the primary challenges facing the Single-Use Bioprocessing Systems market is the limited reusability of materials, which contributes to environmental concerns. Single-use systems are designed for one-time use, leading to significant waste generation from disposable components such as bioreactors, filters, and bags. While these systems reduce the need for cleaning and sterilization, they also raise environmental sustainability issues due to the accumulation of plastic waste. The biopharmaceutical industry has increasingly faced pressure from regulators and environmentally conscious consumers to minimize waste and adopt greener solutions. Although manufacturers are making strides in improving the recyclability of disposable components and exploring more sustainable materials like bioplastics, the challenge of waste disposal remains a concern. Addressing these environmental issues is crucial for the continued growth of the single-use systems market, requiring innovations in biodegradable materials or more efficient recycling processes to mitigate the impact of plastic waste generated during production.

High Initial Costs and Integration Complexities

Despite their long-term cost benefits, the initial capital investment for implementing single-use bioprocessing systems can be a significant challenge for some manufacturers, particularly small and mid-sized companies. The purchase of new equipment and the necessary training for personnel can incur high upfront costs. Additionally, integrating these systems into existing biomanufacturing processes can be complex, particularly for organizations with legacy infrastructure. While single-use systems offer advantages in terms of flexibility and scalability, their implementation requires a shift in production methods and may involve adapting workflows or modifying existing facilities. For companies that are accustomed to traditional stainless-steel bioreactors, transitioning to single-use systems can present logistical challenges, especially in terms of compatibility with existing equipment, process validation, and staff training. Overcoming these barriers requires careful planning, upfront investment in research, and staff education, which can be a significant hurdle, especially for companies operating under tight budget constraints.

Market Opportunities

Growth in Biopharmaceuticals and Personalized Medicine

The increasing demand for biopharmaceutical products, including monoclonal antibodies, therapeutic proteins, and vaccines, presents a significant opportunity for the single-use bioprocessing systems market. The growing focus on personalized medicine, which requires tailored therapies based on an individual's genetic makeup, has created a need for highly flexible and scalable manufacturing systems. Single-use technologies, with their ability to easily scale production and accommodate varying batch sizes, are well-suited for personalized medicine production. As biopharmaceutical companies seek to reduce time-to-market and lower operational costs, the flexibility and efficiency offered by single-use systems provide a competitive advantage. This trend is expected to continue as the demand for biologics increases, fueling the market for single-use bioprocessing technologies that support the manufacture of both small and large batches of personalized therapies.

Expanding Cell and Gene Therapy Market

The rapid expansion of cell and gene therapies offers another major opportunity for the single-use bioprocessing systems market. As these therapies become increasingly popular for treating genetic disorders, cancers, and other complex diseases, there is a rising need for flexible and efficient manufacturing systems that can support the production of highly specialized and small-scale batches. Single-use systems are particularly well-suited for this market, as they offer the necessary scalability, minimize contamination risks, and simplify production processes. With continued advances in gene editing technologies and significant investments in gene therapy research, single-use bioprocessing systems are positioned to play a crucial role in enabling the large-scale production of these innovative treatments. The growing interest and regulatory support for cell and gene therapies will likely accelerate demand for these systems, creating substantial market opportunities.

Market Segmentation Analysis

By Component

Single-use bioprocessing components, including mixers, bioprocess containers, transfer and storage bags, sampling systems, and other accessories, are essential for modern biomanufacturing. Single-use mixers are critical for blending materials like cell cultures and buffers, offering efficient, contamination-free mixing without the need for cleaning, making them ideal for small to medium-scale production. Bioprocess containers, used for storing and transporting materials such as media and cell cultures, are growing in demand due to their flexibility, ease of use, and cost-effectiveness in biologic and cell therapy production. Transfer and storage bags provide a sterile, contamination-free solution for the safe handling and storage of bioprocessing materials, serving as a flexible and cost-efficient alternative to stainless-steel systems. Sampling systems ensure quality control by allowing for precise, sterile sample collection, supporting various biopharmaceutical applications. Additionally, other single-use components like sensors, filters, and valves further contribute to scalable and efficient production in the biopharmaceutical industry.

By Application

The Single-Use Bioprocessing Systems market is significantly driven by two key applications: Research & Development (R&D) and Good Manufacturing Practice (GMP) and commercial production. The R&D segment holds substantial market potential, as single-use systems facilitate faster prototyping and clinical trials by reducing the time and costs associated with cleaning and reusing equipment. On the other hand, the GMP and commercial production segment is expected to dominate the market, as single-use technologies optimize production efficiency, scalability, and regulatory compliance. These systems enable biomanufacturers to scale up operations with lower infrastructure costs and enhanced flexibility, making them a crucial element in modern biopharmaceutical production.

Segments

Based on Component

• Mixers
• Bioprocess Containers
• Transfer and Storage Bags
• Sampling Systems
• Others

Based on Application

• Research & Development (R&D)
• GMP and Commercial Production

Based on End User

• Biopharmaceutical Companies
• Contract Research Organizations (CROs)
• Contract Manufacturing Organizations (CMOs)
• Research Institutes
• Others

Based on Region

• North America
  • U.S
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Regional Analysis

North America (40%)

North America holds the largest market share of approximately 40% of the global Single-Use Bioprocessing Systems market. The region is a leader due to the presence of major biopharmaceutical companies, a robust biotechnology sector, and a highly developed healthcare infrastructure. The United States, in particular, is a dominant force, driven by the rapid adoption of biologic drugs and advancements in gene and cell therapies. The region benefits from strong regulatory support, as agencies like the U.S. Food and Drug Administration (FDA) have provided clear guidelines for the use of single-use technologies. Additionally, substantial investments in biomanufacturing and research and development fuel the demand for more flexible and efficient bioprocessing systems. North America's well-established market and growing emphasis on personalized medicine contribute significantly to the continued growth of the single-use bioprocessing systems market.

Europe (30%)

Europe is the second-largest region, accounting for approximately 30% of the global market share. The growth of the market in Europe is propelled by a strong presence of major pharmaceutical and biotechnology companies in countries such as Germany, the United Kingdom, Switzerland, and France. Europe also benefits from favorable regulatory frameworks, with the European Medicines Agency (EMA) playing a crucial role in promoting advanced manufacturing practices, including the use of single-use technologies. Additionally, the increasing demand for biopharmaceutical products, especially monoclonal antibodies and vaccines, is driving the growth of single-use bioprocessing systems in the region. The rise of cell and gene therapies in Europe, supported by extensive government funding and research initiatives, further bolsters the demand for these systems.

Key players

• Sartorius Stedim Biotech
• Danaher Corporation
• Merck KGaA
• Corning
• Avantor
• CESCO Bioengineering Co Ltd
• PBS Biotech Inc
• Distek Inc
• Eppendorf AG
• Celltainer Biotech B.V
• Getinge
• Cellexus Ltd

Competitive Analysis

The Single-Use Bioprocessing Systems market is highly competitive, with key players such as Sartorius Stedim Biotech, Danaher Corporation, and Merck KGaA leading the industry. These companies offer a wide range of products, from bioreactors to filtration systems, and have established strong brand reputations due to their technological advancements and broad product portfolios. Sartorius and Danaher, for instance, lead in innovation, offering comprehensive, scalable solutions with a focus on automation and process optimization. Merck KGaA is recognized for its robust R&D and strategic acquisitions, bolstering its market presence. Smaller players like PBS Biotech and Cellexus Ltd, while not as large, differentiate themselves with specialized products such as advanced cell culture systems and customized bioprocessing solutions. The market is characterized by continuous product innovation, strategic partnerships, and a focus on cost-effective, scalable solutions that meet the growing demand for biopharmaceutical production.

Recent Developments

• In October 2024, Sartorius Stedim Biotech introduced new enhancements to its single-use bioprocessing portfolio, focusing on improving efficiency and scalability in biomanufacturing processes.

• In November 2024, Danaher Corporation announced the launch of a next-generation single-use bioreactor system that features advanced automation capabilities to streamline bioprocessing workflows.

• In December 2024, Merck KGaA unveiled a new line of single-use filtration systems aimed at enhancing the purification process in biopharmaceutical production.

• In October 2024, CESCO Bioengineering announced the release of a new single-use bioreactor designed specifically for small-scale production, enhancing flexibility for research and development purposes.

• In September 2024, PBS Biotech launched an upgraded version of its single-use bioreactor system featuring improved aeration and mixing technologies to optimize cell culture processes.

Market Concentration and Characteristics 

The Single-Use Bioprocessing Systems market exhibits moderate to high concentration, with several leading players dominating the market. Key companies such as Sartorius Stedim Biotech, Danaher Corporation, and Merck KGaA hold substantial market share, leveraging their extensive product portfolios, advanced technologies, and strong global presence. These players often engage in strategic partnerships, acquisitions, and continuous innovation to maintain their competitive edge. While the market is largely driven by these established players, there is also a growing presence of smaller, specialized companies that focus on niche products and offer tailored solutions to meet the specific needs of biopharmaceutical manufacturers. The market is characterized by rapid technological advancements, a focus on scalability and cost-effectiveness, and increasing demand for flexible, contamination-free biomanufacturing solutions. As the industry expands, consolidation and increased competition are expected to further shape the market dynamics.

Report Coverage

The research report offers an in-depth analysis based on Component, Application, End User and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

1. The growing focus on personalized medicine, including cell and gene therapies, will drive the demand for single-use systems. These systems provide the necessary flexibility and scalability for small-scale, high-quality production.

2. The integration of advanced automation and artificial intelligence will enhance process efficiency and reduce human error in single-use bioprocessing systems. This will help improve the consistency and reliability of biomanufacturing processes.

3. As sustainability becomes a priority, innovations in biodegradable materials and better recycling technologies for single-use components will reduce the environmental footprint of biomanufacturing. This will appeal to environmentally conscious consumers and regulatory bodies.

4. The increasing global demand for biologic drugs, vaccines, and monoclonal antibodies will continue to fuel the growth of the market. Single-use systems offer a cost-effective, flexible alternative to traditional bioreactors in large-scale production.

5. Emerging markets, particularly in Asia-Pacific and Latin America, will witness increased adoption of single-use systems due to the growing biopharmaceutical manufacturing industry. These regions offer cost-effective solutions and support high-demand markets.

6. Startups and smaller biotech companies will increasingly adopt single-use bioprocessing systems to meet growing production needs. The scalability and lower capital investment required make these systems ideal for smaller firms focusing on innovation.

7. As biopharmaceutical companies require tailored production solutions, there will be a greater emphasis on customizable single-use systems. Companies will increasingly offer modular and flexible systems designed for specific applications.

8. Regulatory agencies, such as the FDA and EMA, will continue to streamline approval processes for single-use systems. This will drive adoption by ensuring that these technologies meet the necessary standards for clinical and commercial-scale production.

9. Strategic partnerships between single-use system manufacturers, biopharmaceutical companies, and contract manufacturers will continue to grow. These collaborations will focus on improving product offerings and enhancing process efficiency.

10. Future developments in single-use bioprocessing will focus on providing integrated, end-to-end solutions that cover all aspects of biomanufacturing. This will include everything from raw material preparation to final product packaging, ensuring seamless and efficient production processes.

Shift Toward Cost-Effective and Flexible Manufacturing

Single-use bioprocessing systems reduce the need for expensive stainless-steel infrastructure, cleaning, and validation, enabling manufacturers to scale production efficiently and lower operational costs. This flexibility is especially valuable for both large-scale and small-batch biopharmaceutical production.

Growth in Biologics, Vaccines, and Personalized Medicine

The increasing prevalence of chronic diseases and the rise of personalized therapies have driven demand for biologics, monoclonal antibodies, and vaccines. Single-use systems enable rapid, contamination-free production, supporting the fast-paced development and manufacturing needs of these advanced therapies.

Technological Advancements and Automation

Innovations such as advanced sensors, automation, and integration of AI and digital analytics have improved process control, efficiency, and scalability in single-use systems. These advancements help manufacturers optimize yields, reduce human error, and streamline bioprocessing workflows.

Regulatory Support and Streamlined Approvals

Regulatory agencies like the FDA and EMA have provided clear guidance and support for the adoption of single-use technologies, recognizing their benefits in reducing contamination risk and improving production flexibility. This regulatory backing accelerates market adoption and facilitates faster product development cycles.

Expansion of Cell and Gene Therapy Markets

The rapid growth of cell and gene therapies, which require highly flexible and contamination-free manufacturing environments, has increased demand for single-use bioprocessing systems. These systems are ideally suited for small, specialized batches and support the scalability needed for innovative, personalized treatments.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.